Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Head Neck Cancer: early-phase trial registry

5 of 8 indexed Head Neck Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Head Neck Cancer: 8 US clinical trials tracked, 5 recruiting.

Head Neck Cancer is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition head-neck-cancer

OPEN 5 | RECR 63% | LATE 0 | EARLY 7 | RANK #2176 | SPON 2

Nearest open-share peer: Adolescent (63% recruiting · 16 trials)

Activity, Motor75%Head Neck Cancer (this)63%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Head Neck Cancer

Head Neck Cancer lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Head Neck Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Head Neck Cancer is recruiting above its size-band peers.

    5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Head Neck Cancer research.

    Memorial Sloan Kettering Cancer Center accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Head Neck Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 32 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Head Neck Cancer research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 22

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 2 250 participants

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

M.D. Anderson Cancer Center

NCT06912763

RECRUITING Phase 1 41 participants

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

VLP Therapeutics

NCT06736379

RECRUITING Phase 2 32 participants

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Wake Forest University Health Sciences

NCT04858269

RECRUITING NA 20 participants

Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

University of Virginia

NCT07405645

RECRUITING Phase 1 16 participants

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Coordination Pharmaceuticals

NCT05838729

ACTIVE NOT RECRUITING Phase 1 97 participants

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

NextCure

NCT05572684

COMPLETED Phase 1 25 participants

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

Memorial Sloan Kettering Cancer Center

NCT00736619

COMPLETED Phase 1 18 participants

RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT00935961

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2

Named interventions

Most-linked intervention names on Head Neck Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RAD001 + docetaxel + cisplatin Drug
1 trials
Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®) Other
1 trials
VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) Biological
1 trials
VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection) Biological
1 trials
RiMO-301 Drug
1 trials
ExAblate Neuro Device
1 trials
NC410 Drug
1 trials
Pembrolizumab (KEYTRUDA®) Drug
1 trials

US sites by state

Facility locations filed on Head Neck Cancer trials. A trial with sites in several states counts in each.

New York 4 trials
Texas 3 trials
New Jersey 3 trials
Virginia 2 trials
Washington 1 trials
Oregon 1 trials
Ohio 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Head Neck Cancer page

8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head Neck Cancer condition card totals 8 registered trials; most-linked intervention RAD001 + docetaxel + cisplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.